558 related articles for article (PubMed ID: 1380674)
1. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
2. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
3. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
4. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
5. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming.
Kropshofer H; Max H; Halder T; Kalbus M; Muller CA; Kalbacher H
J Immunol; 1993 Nov; 151(9):4732-42. PubMed ID: 8409432
[TBL] [Abstract][Full Text] [Related]
6. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
7. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.
Kirschmann DA; Duffin KL; Smith CE; Welply JK; Howard SC; Schwartz BD; Woulfe SL
J Immunol; 1995 Dec; 155(12):5655-62. PubMed ID: 7499850
[TBL] [Abstract][Full Text] [Related]
8. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins.
Zavala-Ruiz Z; Strug I; Anderson MW; Gorski J; Stern LJ
Chem Biol; 2004 Oct; 11(10):1395-402. PubMed ID: 15489166
[TBL] [Abstract][Full Text] [Related]
9. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
[TBL] [Abstract][Full Text] [Related]
10. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides.
Vogt AB; Kropshofer H; Kalbacher H; Kalbus M; Rammensee HG; Coligan JE; Martin R
J Immunol; 1994 Aug; 153(4):1665-73. PubMed ID: 7519208
[TBL] [Abstract][Full Text] [Related]
11. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
12. Class I MHC-peptide interaction: structural and functional aspects.
Ruppert J; Kubo RT; Sidney J; Grey HM; Sette A
Behring Inst Mitt; 1994 Jul; (94):48-60. PubMed ID: 7998914
[TBL] [Abstract][Full Text] [Related]
13. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
14. MHC class II binding of peptides derived from HLA-DR 1.
Harris PE; Liu Z; Suciu-Foca N
J Immunol; 1992 Apr; 148(7):2169-74. PubMed ID: 1545124
[TBL] [Abstract][Full Text] [Related]
15. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations.
Chen Y; Sidney J; Southwood S; Cox AL; Sakaguchi K; Henderson RA; Appella E; Hunt DF; Sette A; Engelhard VH
J Immunol; 1994 Mar; 152(6):2874-81. PubMed ID: 8144888
[TBL] [Abstract][Full Text] [Related]
16. HLA-DP2: self peptide sequences and binding properties.
Chicz RM; Graziano DF; Trucco M; Strominger JL; Gorga JC
J Immunol; 1997 Nov; 159(10):4935-42. PubMed ID: 9366419
[TBL] [Abstract][Full Text] [Related]
17. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
18. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands.
Marshall KW; Liu AF; Canales J; Perahia B; Jorgensen B; Gantzos RD; Aguilar B; Devaux B; Rothbard JB
J Immunol; 1994 May; 152(10):4946-57. PubMed ID: 8176213
[TBL] [Abstract][Full Text] [Related]
19. Naturally processed HLA class I bound peptides from c-myc-transfected cells reveal allele-specific motifs.
Harris PE; Colovai A; Liu Z; Dalla Favera R; Suciu-Foca N
J Immunol; 1993 Dec; 151(11):5966-74. PubMed ID: 8245441
[TBL] [Abstract][Full Text] [Related]
20. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
